170 related articles for article (PubMed ID: 36947513)
1. Redox metabolism maintains the leukemogenic capacity and drug resistance of AML cells.
Huang D; Zhang C; Xiao M; Li X; Chen W; Jiang Y; Yuan Y; Zhang Y; Zou Y; Deng L; Wang Y; Sun Y; Dong W; Zhang Z; Xie L; Yu Z; Chen C; Liu L; Wang J; Yang Y; Yang J; Zhao Y; Zheng J
Proc Natl Acad Sci U S A; 2023 Mar; 120(13):e2210796120. PubMed ID: 36947513
[TBL] [Abstract][Full Text] [Related]
2. NADPH metabolism determines the leukemogenic capacity and drug resistance of AML cells.
Chen C; Lai X; Zhang Y; Xie L; Yu Z; Dan S; Jiang Y; Chen W; Liu L; Yang Y; Huang D; Zhao Y; Zheng J
Cell Rep; 2022 Apr; 39(1):110607. PubMed ID: 35385727
[TBL] [Abstract][Full Text] [Related]
3. Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia.
Hosseini M; Rezvani HR; Aroua N; Bosc C; Farge T; Saland E; Guyonnet-Dupérat V; Zaghdoudi S; Jarrou L; Larrue C; Sabatier M; Mouchel PL; Gotanègre M; Piechaczyk M; Bossis G; Récher C; Sarry JE
Cancer Res; 2019 Oct; 79(20):5191-5203. PubMed ID: 31358527
[TBL] [Abstract][Full Text] [Related]
4. Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia.
Di Marcantonio D; Martinez E; Sidoli S; Vadaketh J; Nieborowska-Skorska M; Gupta A; Meadows JM; Ferraro F; Masselli E; Challen GA; Milsom MD; Scholl C; Fröhling S; Balachandran S; Skorski T; Garcia BA; Mirandola P; Gobbi G; Garzon R; Vitale M; Sykes SM
Clin Cancer Res; 2018 Feb; 24(3):608-618. PubMed ID: 29127121
[No Abstract] [Full Text] [Related]
5. p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia.
Zhang J; Seet CS; Sun C; Li J; You D; Volk A; Breslin P; Li X; Wei W; Qian Z; Zeleznik-Le NJ; Zhang Z; Zhang J
Mol Oncol; 2013 Dec; 7(6):1069-82. PubMed ID: 23988911
[TBL] [Abstract][Full Text] [Related]
6. Genetically encoded redox biosensor system for H
Cui M; Abbas G; Wang D; Liu Q; Gong R; Li M; Zhang XE
Sci China Life Sci; 2022 Jun; 65(6):1259-1262. PubMed ID: 35192125
[No Abstract] [Full Text] [Related]
7. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
8. Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease.
Risueño RM; Campbell CJ; Dingwall S; Levadoux-Martin M; Leber B; Xenocostas A; Bhatia M
Blood; 2011 Jun; 117(26):7112-20. PubMed ID: 21562049
[TBL] [Abstract][Full Text] [Related]
9. Targeting human mitochondrial NAD(P)
Chen KC; Hsiao IH; Huang YN; Chou YT; Lin YC; Hsieh JY; Chang YL; Wu KH; Liu GY; Hung HC
Cell Oncol (Dordr); 2023 Oct; 46(5):1301-1316. PubMed ID: 37079187
[TBL] [Abstract][Full Text] [Related]
10. The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia.
Niederkorn M; Ishikawa C; M Hueneman K; Bartram J; Stepanchick E; R Bennett J; E Culver-Cochran A; Bolanos LC; Uible E; Choi K; Wunderlich M; Perentesis JP; M Chlon T; Filippi MD; Starczynowski DT
Leukemia; 2022 Feb; 36(2):438-451. PubMed ID: 34465865
[TBL] [Abstract][Full Text] [Related]
11. NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML.
Sasca D; Szybinski J; Schüler A; Shah V; Heidelberger J; Haehnel PS; Dolnik A; Kriege O; Fehr EM; Gebhardt WH; Reid G; Scholl C; Theobald M; Bullinger L; Beli P; Kindler T
Blood; 2019 May; 133(21):2305-2319. PubMed ID: 30814062
[TBL] [Abstract][Full Text] [Related]
12. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
[TBL] [Abstract][Full Text] [Related]
13. TWIST-1 promotes cell growth, drug resistance and progenitor clonogenic capacities in myeloid leukemia and is a novel poor prognostic factor in acute myeloid leukemia.
Wang N; Guo D; Zhao YY; Dong CY; Liu XY; Yang BX; Wang SW; Wang L; Liu QG; Ren Q; Lin YM; Ma XT
Oncotarget; 2015 Aug; 6(25):20977-92. PubMed ID: 26023795
[TBL] [Abstract][Full Text] [Related]
14. WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target.
Zhou B; Jin X; Jin W; Huang X; Wu Y; Li H; Zhu W; Qin X; Ye H; Gao S
J Transl Med; 2020 Jun; 18(1):254. PubMed ID: 32580769
[TBL] [Abstract][Full Text] [Related]
15. Repressing malic enzyme 1 redirects glucose metabolism, unbalances the redox state, and attenuates migratory and invasive abilities in nasopharyngeal carcinoma cell lines.
Zheng FJ; Ye HB; Wu MS; Lian YF; Qian CN; Zeng YX
Chin J Cancer; 2012 Nov; 31(11):519-31. PubMed ID: 23114090
[TBL] [Abstract][Full Text] [Related]
16. ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.
Wang Y; Skibbe JR; Hu C; Dong L; Ferchen K; Su R; Li C; Huang H; Weng H; Huang H; Qin X; Jin J; Chen J; Jiang X
Sci Rep; 2017 May; 7(1):1853. PubMed ID: 28500307
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow niche ATP levels determine leukemia-initiating cell activity via P2X7 in leukemic models.
He X; Wan J; Yang X; Zhang X; Huang D; Li X; Zou Y; Chen C; Yu Z; Xie L; Zhang Y; Liu L; Li S; Zhao Y; Shao H; Yu Y; Zheng J
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33301426
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia.
Zhou J; Bi C; Ching YQ; Chooi JY; Lu X; Quah JY; Toh SH; Chan ZL; Tan TZ; Chong PS; Chng WJ
J Hematol Oncol; 2017 Jul; 10(1):138. PubMed ID: 28693523
[TBL] [Abstract][Full Text] [Related]
19. HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia.
Zhu G; Luo H; Feng Y; Guryanova OA; Xu J; Chen S; Lai Q; Sharma A; Xu B; Zhao Z; Feng R; Ni H; Claxton D; Guo Y; Mesa RA; Qiu Y; Yang FC; Li W; Nimer SD; Huang S; Xu M
Nat Commun; 2021 Mar; 12(1):1956. PubMed ID: 33782403
[TBL] [Abstract][Full Text] [Related]
20. Transient potential receptor melastatin-2 (Trpm2) does not influence murine MLL-AF9-driven AML leukemogenesis or in vitro response to chemotherapy.
Haladyna JN; Pastuer T; Riedel SS; Perraud AL; Bernt KM
Exp Hematol; 2016 Jul; 44(7):596-602.e3. PubMed ID: 27033163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
